Milestone Scientific Q1 Operating Loss Reduced to $828K
Milestone Scientific reported Q1 2026 financial results, showing a significant reduction in operating loss to $828,000 from $2.0 million in the prior year, and an improved net loss of $840,000. Total revenue remained relatively stable at $2.16 million, despite challenges in shipping orders to the Middle East, with medical business revenue more than doubling year-over-year. The company reaffirmed its 2026 revenue outlook of $9.8 million to $10.2 million, expecting double-digit growth, and completed a $2.15 million financing post-quarter end to strengthen its balance sheet. Milestone Scientific aims to achieve cash flow breakeven in early 2027 and addressed the going concern explanatory paragraph from its 2025 10-K, citing improved liquidity and operational outlook.
Key Highlights
- Q1 2026 operating loss reduced to $828,000 from $2.0 million in Q1 2025.
- Q1 2026 net loss improved to $840,000, or $(0.01) per share, from $2.0 million, or $(0.02) per share.
- Q1 2026 total revenue was $2.16 million, compared to $2.23 million in Q1 2025.
- Medical business revenue more than doubled year-over-year in Q1 2026.
- Operating expenses were reduced by more than 30% year-over-year.
- Reaffirmed 2026 revenue outlook of $9.8 million to $10.2 million, representing double-digit growth.
- Completed a $2.15 million financing subsequent to quarter end on April 20, 2026.
Price Impact
More from MLSS